Loading
Loading
Research Overview
Vasoactive intestinal peptide; activates VPAC1/VPAC2 receptors to produce potent vasodilation, suppress pro-inflammatory cytokines, and regulate circadian rhythms; also demonstrated immunomodulatory effects in autoimmune and pulmonary hypertension models.
Overview
VIP is a member of the glucagon/secretin peptide superfamily that acts through two G-protein coupled receptors, VPAC1 and VPAC2, expressed on smooth muscle, immune cells, neurons, and peripheral tissues. Preclinical research has characterised VIP's vasodilatory effects in vascular smooth muscle, its anti-inflammatory actions through immune cell VPAC receptor engagement, and its role as a circadian pacemaker signal from the suprachiasmatic nucleus in animal model systems.
In preclinical respiratory research, VIP has been extensively studied as a bronchodilator and regulator of airway smooth muscle tone, mucus secretion, and inflammatory cell activity in relevant animal model systems. Its expression in non-adrenergic non-cholinergic (NANC) neurons of the respiratory tract has been characterised in preclinical neuroanatomical and pharmacological studies.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, vip (vasoactive intestinal peptide) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Vasoactive intestinal peptide; activates VPAC1/VPAC2 receptors to produce potent vasodilation, suppress pro-inflammatory cytokines, and regulate circadian rhythms; also demonstrated immunomodulatory effects in autoimmune and pulmonary hypertension models.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.